Correlation Between Neurosense Therapeutics and Allarity Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Neurosense Therapeutics and Allarity Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neurosense Therapeutics and Allarity Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Neurosense Therapeutics and Allarity Therapeutics, you can compare the effects of market volatilities on Neurosense Therapeutics and Allarity Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neurosense Therapeutics with a short position of Allarity Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neurosense Therapeutics and Allarity Therapeutics.

Diversification Opportunities for Neurosense Therapeutics and Allarity Therapeutics

0.57
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Neurosense and Allarity is 0.57. Overlapping area represents the amount of risk that can be diversified away by holding Neurosense Therapeutics and Allarity Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Allarity Therapeutics and Neurosense Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neurosense Therapeutics are associated (or correlated) with Allarity Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Allarity Therapeutics has no effect on the direction of Neurosense Therapeutics i.e., Neurosense Therapeutics and Allarity Therapeutics go up and down completely randomly.

Pair Corralation between Neurosense Therapeutics and Allarity Therapeutics

Given the investment horizon of 90 days Neurosense Therapeutics is expected to generate 0.87 times more return on investment than Allarity Therapeutics. However, Neurosense Therapeutics is 1.16 times less risky than Allarity Therapeutics. It trades about -0.12 of its potential returns per unit of risk. Allarity Therapeutics is currently generating about -0.31 per unit of risk. If you would invest  134.00  in Neurosense Therapeutics on September 16, 2024 and sell it today you would lose (48.00) from holding Neurosense Therapeutics or give up 35.82% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Neurosense Therapeutics  vs.  Allarity Therapeutics

 Performance 
       Timeline  
Neurosense Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Neurosense Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.
Allarity Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Allarity Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with inconsistent performance in the last few months, the Stock's essential indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Neurosense Therapeutics and Allarity Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Neurosense Therapeutics and Allarity Therapeutics

The main advantage of trading using opposite Neurosense Therapeutics and Allarity Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neurosense Therapeutics position performs unexpectedly, Allarity Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allarity Therapeutics will offset losses from the drop in Allarity Therapeutics' long position.
The idea behind Neurosense Therapeutics and Allarity Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Other Complementary Tools

Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments